KTKatherine E. Talcott

Katherine E. Talcott

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katherine E. Talcott has a total of 175 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characterization of Diabetic Retinopathy in Trimesters of Pregnancy

    by Kanika Seth, Neil A. Rana, Jason M. Singer, Rishi P. Singh, Katherine E. Talcott

    Purpose: To evaluate the relationship between trimester of pregnancy and stage of diabetic retinopathy (DR) in a cohort of women with diabetes. Methods: In this single-center, retrospective cohort study, data were collected from adult women with diabetes who experienced a pregnancy at 5 timepoints: prepregnancy, each trimester, and postpregnancy. Progression, manifestation, and improvement of DR were tracked via logistic regression. Results: A total of 158 patients were analyzed. Among them, 13 (8.2%) showed progression to worse stage of DR during pregnancy, of whom 6.9%, 5.0%, and 14.3% had progression within the prepregnancy/first trimester, second trimester, and third trimester brackets, respectively, and 10.0% progressed postpregnancy; differences between the trimesters regarding incidence of DR progression were nonsignificant ( P = .42). Of patients with no retinopathy at baseline, 4.62%, 7.69%, and 5.88% developed DR in each of the 3 trimesters, respectively, and 6.45% developed DR postpregnancy; differences in rates of DR manifestation were nonsignificant ( P = .97). Conclusions: Pregnancy stage was not associated with risk of DR manifestation or progression in this cohort.

  • Examination of Alzheimer Disease and Antidementia Medications’ Effect on Age-Related Macular Degeneration

    by Sonia B. Kim, Hejin Jeong, David C. Kaelber, Rishi P. Singh, Katherine E. Talcott

    Purpose: To clarify the prevalence of age-related macular degeneration (AMD) in Alzheimer disease and assess whether antidementia medications modify this relationship. Methods: A retrospective cohort study was performed using electronic health record data (TriNetX) of adults aged 65 years and older with 10 or more years of ophthalmology follow-up. Patients with Alzheimer disease were compared with controls to estimate unadjusted and propensity score–adjusted prevalence odds ratios (ORs) for any AMD and progression to advanced AMD. Within the Alzheimer disease cohort, associations between duration of exposure to antidementia medication and AMD were evaluated. Results: AMD prevalence was higher in patients with Alzheimer disease (n = 4257) compared with controls (n = 140 378) before (prevalence OR, 1.57; 95% CI, 1.46-1.69), but not after adjustment (adjusted prevalence OR, 1.03; 95% CI, 0.92-1.15). Advanced AMD prevalence was comparable between cohorts, and no association was found between exposure to antidementia medication and AMD risk. Conclusions: fter adjustment for confounders, Alzheimer disease and antidementia medications were not associated with AMD development or progression.

  • Open Access

    The Structure–Function Link of Ellipsoid Zone Integrity and Outer Retinal Features with Visual Acuity in Dry AMD

    by Reem Amine, Masaharu Mizuno, Karen Matar, Asmita Indurkar, Paulo Simoes, Ming Hu, Rachel A. Downes, Katherine E. Talcott, Jamie L. Reese, Justis P. Ehlers

    Background/Objectives: The purpose of this study was to evaluate associations between quantitative ellipsoid zone (EZ) integrity metrics derived from spectral-domain OCT (SD-OCT) and visual outcomes, including clinically meaningful visual acuity (VA) loss, in dry age-related macular degeneration (AMD). Methods: This single-center retrospective image-analysis cohort included 351 eyes from 351 patients with intermediate AMD or atrophic changes. Macular SD-OCT scans were analyzed using a certified-reader-validated machine learning-based segmentation platform to delineate the EZ, retinal pigment epithelium (RPE), and Bruch’s membrane (BM). EZ metrics included EZ-RPE thickness (i.e., outer segment thickness) and EZ attenuation, defined as partial attenuation (EZ-RPE thickness of ≤20 µm, abnormal outer segment thinning)) or total attenuation/loss (0 µm). Drusen volume was quantified from the RPE-BM compartment. VA was converted to ETDRS letters. Associations between baseline OCT metrics and baseline VA, Year 2 VA, and ≥15-letter VA loss were assessed using nonparametric testing, linear regression, and ANCOVA. Results: Greater EZ-RPE thickness and lower EZ attenuation were associated with better baseline VA (all p < 0.001), and EZ metrics remained significant in cross-sectional regression models. Among 188 eyes with Year 2 follow-up, 38 (20%) experienced ≥15-letter VA loss. These eyes had significantly lower baseline EZ-RPE thickness (i.e., abnormal outer segment thinning) and greater EZ attenuation than eyes without such loss (all p < 0.001). In ANCOVA models, EZ metrics remained associated with Year 2 VA (all p < 0.001), whereas drusen volume was not. Conclusions: Quantitative EZ integrity metrics were associated with cross-sectional and longitudinal visual outcomes in dry AMD. EZ-RPE thickness and EZ attenuation may serve as clinically relevant OCT biomarkers reflecting photoreceptor integrity and risk of meaningful VA loss.

  • Initial Impact of Loss of Copay Assistance From a National Nonprofit Fund on Outcomes of Retinal Disease

    by Victor Bellanda, Suraj Bala, Gabriel Castilho S. Barbosa, Nitesh Mohan, Matthew J. Schulgit, Amy S. Babiuch, Alex Yuan, Ananth Sastry, Katherine E. Talcott, Diana McOwen, et al.

    Purpose: Many patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or retinal vein occlusion who have lost copay assistance from the DBA Good Days national charity fund have been forced to switch treatment from branded intravitreal antivascular endothelial growth factor (anti-VEGF) therapy to bevacizumab. This study sought to characterize the short-term impact of these changes on clinical outcomes. Methods: This retrospective study included 89 eyes of 69 patients with nAMD, DME, or retinal vein occlusion who transitioned from receiving branded anti-VEGF therapy (aflibercept 2.0 mg or 8.0 mg; faricimab) to bevacizumab. The primary endpoint was changes from baseline in central subfield thickness (CST) after 1, 2, and 3 injections. Secondary endpoints included changes in best-corrected visual acuity (BCVA), intraocular pressure, intraretinal fluid, subretinal fluid, pigment epithelial detachment, injection intervals, predictors of poor outcome (BCVA loss of ≥15 Early Treatment Diabetic Retinopathy Study letters or CST increase of ≥50 µm), and switchback to branded therapy. Results: From baseline to after the third bevacizumab injection, the CST increased from a mean (±SD) 228.7 ± 52.3 µm to 271.3 ± 40.0 µm in the overall cohort ( P = .004), and from 224.1 ± 50.6 µm to 268.6 ± 38.5 µm among nAMD eyes ( P = .007). The injection interval decreased from a median 8.6 weeks (interquartile range [IQR], 7.0–10.9 weeks) preswitch to 7.5 weeks (IQR, 5.3–9.5 weeks) after 3 injections ( P < .001). Fourteen eyes (15.7%) met the criteria for poor outcome, and 15 (16.9%) were switched back to branded therapy. Worsening intraretinal fluid was an early indicator of suboptimal response, and shorter preswitch injection intervals were a predictor of switching back to branded therapy. Conclusions: Switching from branded anti-VEGF therapy to bevacizumab was associated with anatomic worsening and shorter injection intervals. Shorter preswitch intervals and early postswitch intraretinal fluid changes may help identify patients at risk for poor outcomes.

  • Open Access

    Demographic Disparities in the Likelihood of Surgical Repair Following Diagnosis of Rhegmatogenous Retinal Detachment

    by Ashvin Babu, Sonia B. Kim, David C. Kaelber, Rishi P. Singh, Aleksandra V. Rachitskaya, Katherine E. Talcott

  • Open Access

    Evaluation of the Impact of Gamma-Aminobutyric Acid on Diabetic Retinopathy in a Large US Population-Based Cohort

    by Sonia B. Kim, Melody Y. Zhou, Kevin C. Allan, David C. Kaelber, Amy S. Babiuch, Rishi P. Singh, Katherine E. Talcott


  • Recombinant Zoster Vaccine Uptake in Patients with Noninfectious Ocular Inflammatory Diseases Receiving Immunosuppression

    by Kevin Xu, Sonia B. Kim, Alison H. Zhao, David C. Kaelber, Rishi P. Singh, Katherine E. Talcott, Danny A. Mammo

  • The Impact of PCSK9 Inhibitors on Development of Retinal Vascular Occlusions

    by Isabella H. Yazji, Nadia J. Abbass, David C. Kaelber, Katherine E. Talcott, Rishi P. Singh

  • Long-Term Predictive Value of Macular Thickness Fluctuations in Response to Anti-VEGF Treatment for Age-Related Macular Degeneration

    by Alison H. Zhao, Taseen A. Alam, Nikhil Das, Christopher Maatouk, Rishi P. Singh, Katherine E. Talcott

    Purpose: To evaluate whether macular thickness fluctuations are predictive of long-term visual outcomes in patients with neovascular age-related macular degeneration (nAMD) after treatment initiation with antivascular endothelial growth factor (anti-VEGF). Methods: Patients with nAMD treated with anti-VEGF intravitreal injections for 3 and 5 years were evaluated. Anatomic parameters, including central subfield thickness (CST), were evaluated with optical coherence tomography. The cohort was segregated into quartiles based on CST variability over the initial 12 months of treatment. Kruskal-Wallis tests were used to compare 3- and 5-year final best-corrected visual acuity (BCVA), change in BCVA, final CST, and change in CST among quartiles. Multiple linear regression analyses were subsequently performed. Results: Three hundred sixty-six eyes were included in the 3-year analysis and 275 eyes in the 5-year analysis. Patients received an average of 8.4 injections over 12 months and had a final mean BCVA of 60.7 Early Treatment Diabetic Retinopathy Study letters. Those with the greatest CST variability demonstrated significantly lower baseline and final BCVA compared with other quartiles, alongside lower baseline BCVA values. No difference was found between quartiles for final CST and change in BCVA. Multiple linear regression analyses demonstrated that macular thickness variability characterized by the standard deviation of CST, baseline VA, and age was a significant predictor of VA after 3 and 5 years. Conclusions: Macular thickness variability was a statistically significant correlate and limited predictor of long-term response to visual outcomes at 3 and 5 years after anti-VEGF initiation. Macular thickness variability may be a biomarker with limited long-term predictive value in patients with nAMD.